CRISPR is best known as a gene-editing tool, but it is also changing molecular diagnostics. In this spotlight session, Dr. Arvind Murali Venkatesan, CEO of CRISPR Bits, explains how the company's PathCrisp platform pairs amplification with CRISPR-based detection to deliver fast, accurate and affordable testing. He walks through applications in sickle cell disease and antimicrobial resistance, field validation results, and the steps needed to bring decentralised molecular testing closer to patients.

CrisprBits: Translating CRISPR into Next-Generation Diagnostics

At Healthark, we are proud to host the third edition of RISE Health Innovation Summit 2026 - formerly RWEsearch & Health Innovation Summit - a dedicated platform for stakeholders across the life sciences ecosystem to engage in high-quality dialogue, learning, and action. In an era defined by data-driven decision-making and accelerated innovation, the convergence of real-world evidence, AI, clinical research, and emerging science has never been more critical.

RISE 2026 unites visionaries and change-makers from around the world across seven disciplines – Real-World Evidence, AI & Automation, Clinical Trials & Research, Cell & Gene Therapy, Regulatory Science, Indian Healthcare, and Global Capability Centers. Together, we spark collaborative thinking across domains and accelerate the transformation of healthcare through the power of science, evidence, and innovation.

Dr. Arvind Venkatesan

3

1.5k

8.2k

4.7

Sessions Taken

75

5

484

4.5

484

4.5